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1. Introduction
Pharmaceuticals in general have contributed significantly to improvements in 
the quality of life of both humans and animals. Pharmaceuticals used for either 
human or veterinary purposes have the ability to delay the onset of disease, relieve 
symptoms, and cure and prevent complications. In all, the quality of life gets 
improved with the use and application of pharmaceuticals.
Veterinary pharmaceuticals are needed not only for the ultimate economic 
benefits they provide but for ensuring that animals are healthy. Quite a significant 
number of veterinary drugs are available for different purposes and application. 
These include antibiotics used to fight and destroy bacteria; anthelmintics used to 
destroy internal parasites; insecticides used to destroy ticks, lice, fleas, and mites; 
and hormones used for growth and fertility promotion [1].
Broadly, four main categories of veterinary pharmaceuticals have been identi-
fied, and these are (i) prophylaxis agents used to prevent diseases, (ii) metaphylaxis 
agents used to control the spread of illness, (iii) therapeutic agents for the treat-
ment of various forms of diseases, and (iv) growth promoters used to stimulate 
growth rate [1].
The development, formulation, preparation at point of use, quality assessment, 
dosage forms, distribution, stability, use and storage, occurrence, and persistence 
in the environment as well as their disposal and regulatory control require skilled 
knowledge and expertise to ensure their effective handling.
There is therefore the need to ensure that animal food for human consump-
tion contain very minimal level and if possible devoid of any potential hazardous 
veterinary drug residues.
This would help ensure the successful achievement of human health needs.
The transfer of potentially hazardous veterinary pharmaceutical residues from 
animal food (in residual levels) to humans through the food chain could pose 
detrimental health issues to humans.
Public health-related issues and potential risks to humans (intrinsic toxicity, 
residual levels, and antimicrobial resistance especially and environmental con-
tamination from waste of animals) from un-guarded and routine administration 
of veterinary pharmaceuticals have necessitated the need for stringent global, 
international, and national regulations as well as safety standards for veterinary 
pharmaceuticals.
Veterinary pharmaceuticals are usually formulated considering certain key 
factors such as the anatomy of the animal, bioavailability of the drug molecule, 
and other pharmacodynamic and pharmacokinetic parameters. For example, 
one cannot lay hands easily on an injectable or powder form of oxytetracycline 
employed for human purposes. Oxytetracycline is presented in the form of 
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capsules and tablets for humans. However, feed premixes, injectables, soluble 
powders, and tablet dosage forms of oxytetracycline have been formulated for 
animals.
The active ingredients (in veterinary medicines) may also differ in kind and 
amount compared to human medicines [2]. For instance, doses as low as 50 mg 
for oxytetracycline may be administered to animals, which is far below the recom-
mended daily dosage for humans.
The approval processes for veterinary pharmaceuticals and human drugs are 
separate in most cases, though similar [2].
It is increasingly becoming evident that data on the quantities of veterinary 
pharmaceuticals employed from national levels are lacking. Such data are obtained 
or provided on voluntary basis and very little transparency is involved [3–5].
Furthermore, political, commercial, and economic interests of veterinary phar-
maceutical manufacturers do not always commensurate with the required public 
health interests.
Thus, a well-coordinated strategy needed to identify reliable scientific data 
with the right correlated research designs and methods from relevant stakehold-
ers is needed to address such pertinent issues. With this background, holistic 
contributions from researchers, scientists, and well-meaning stakeholders would 
be required in addressing the myriad of issues arising from the use of veterinary 
pharmaceuticals. Such agenda must, thus, include contributions from experts in 
clinical sciences (e.g., veterinary medicine and human medicine), basic sciences 
(e.g., genetics and microbiology), social sciences (e.g., anthropology and sociol-
ogy), economics (e.g., health and agriculture), public health (e.g., epidemiology 
and nursing), and policy makers (e.g., legislative and regulatory) to achieve 
desired goals.
The in-depth information, data, and some policy directions needed to address 
such issues are what this book provides. For example, the challenge of finding 
new bioactive compounds from plant sources, needed to treat infectious diseases, 
hitherto, not responding to already available antimicrobial agents, is covered in this 
book.
The use of various plant extracts in the management of foot and mouth disease 
virus is well discussed in this book.
Moreover, lots of exposure on current trends in analytical techniques needed for 
the determination of residual levels of veterinary pharmaceuticals in animal food 
products is also well expounded.
The contents of this book, together with ongoing and future research, would in 
the long term help provide and address well-structured scientific agenda and objec-
tives related to veterinary pharmaceuticals. This would ultimately help surmount 
challenges associated with the manufacture, use, and collection of data associated 
with veterinary pharmaceuticals.
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